Showing results (1-10 of 286) with videos related to

Sort By:
Pageof 29
Experimental Gerontology|March 15, 2005
Benign prostatic hyperplasia: age-related tissue-remodelingGerold Untergasser, Stephan Madersbacher, Peter Berger
Experimental Gerontology|July 22, 2008
Aging of the prostate epithelial stem/progenitor cellChristoph Zenzmaier, Gerold Untergasser, Peter Berger
The Prostate|April 1, 2005
Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cellsGerold Untergasser, Eugen Plas, Gerald Pfister, et al.
Wiener Klinische Wochenschrift|August 30, 2008
[Pathophysiology and therapy of benign prostatic hyperplasia]Natalie Sampson, Stephan Madersbacher, Peter Berger
Mechanisms of Ageing and Development|December 22, 2004
Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiationGerold Untergasser, Roland Gander, Claudia Lilg, et al.
Endocrinology|June 18, 2010
Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasiaChristoph Zenzmaier, Natalie Sampson, Dominik Pernkopf, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 2002
Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha productionHolger Rumpold, Katarina Mascher, Gerold Untergasser, et al.
The Prostate|February 6, 2008
Dysregulation of Dkk-3 expression in benign and malignant prostatic tissueChristoph Zenzmaier, Gerold Untergasser, Martin Hermann, et al.
The Prostate|September 21, 2002
Neuroendocrine differentiation of human prostatic primary epithelial cells in vitroHolger Rumpold, Elmar Heinrich, Gerold Untergasser, et al.
Endocrinology|September 6, 2012
Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiationChristoph Zenzmaier, Johann Kern, Natalie Sampson, et al.
Pageof 29